Abnormalities of hemostasis in ischemic stroke

Area of Science:

• Neurology
• Hematology
• Vascular Medicine

Background:

• A significant percentage of brain infarction cases remain unexplained despite advanced diagnostics.
• Hypercoagulability is a potential cause for a substantial portion of these unexplained strokes.
• Hemostatic abnormalities, both familial and acquired, are implicated in stroke pathogenesis.

Purpose of the Study:

• To review the classification and implications of familial and acquired hemostatic abnormalities in stroke.
• To highlight the association of antiphospholipid antibody syndrome with thrombotic events.
• To emphasize the role of endothelial dysfunction and anticoagulant protein abnormalities in stroke.

Main Methods:

• Literature review and synthesis of existing research on hemostatic disorders and stroke.
• Classification of thrombotic coagulopathies into familial and acquired categories.
• Discussion of specific conditions such as protein deficiencies, sickle cell disease, and antiphospholipid antibody syndrome.

Main Results:

• Familial thrombotic coagulopathies include deficiencies in protein-C, protein-S, and antithrombin III, alongside conditions like sickle cell disease and homocystinuria.
• Acquired disorders, notably antiphospholipid antibody syndrome, are strongly linked to stroke, though mechanisms and treatments are not fully understood.
• Many acquired abnormalities occur in specific clinical settings like malignancy or myeloproliferative diseases, potentially sharing pathways with inherited disorders.

Conclusions:

• Hemostatic disorders in stroke often involve vascular endothelial dysfunction and impaired natural anticoagulant proteins.
• Further understanding of these hemostatic abnormalities is crucial for improving stroke diagnosis and treatment strategies.
• Targeting hypercoagulability and associated hemostatic defects offers potential for better stroke prevention and management.